BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2026)

BioXcel Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $132.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 5.89% year-over-year to $132.9 million in Q1 2026; TTM through Mar 2026 was $132.9 million, a 5.89% increase from a year earlier, with the FY2025 full-year figure at $138.6 million, up 11.04% from the prior year.
• Total Non-Current Liabilities fell to $132.9 million in Q1 2026 per BTAI's latest filing, from $138.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $139.0 million in Q3 2023 and bottomed at $82.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $130.1 million (2024), against an average of $126.6 million.
• Across the five-year window, Total Non-Current Liabilities surged 61.19% in 2023 and dropped 6.38% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $126.7 million in 2022, then gained by 1.24% to $128.3 million in 2023, then retreated by 2.73% to $124.8 million in 2024, then gained by 11.04% to $138.6 million in 2025, then fell by 4.14% to $132.9 million in 2026.
• Per Business Quant, the three latest BTAI Total Non-Current Liabilities figures stand at $132.9 million (Q1 2026), $138.6 million (Q4 2025), and $130.1 million (Q3 2025).